tbuckley/cabot-search huggingface dataset:
Depressive symptoms in lung transplant recipients: trajectory and association with mortality and allograft dysfunction
Authors: Nicholas A Kolaitis, Ying Gao, Allison Soong, John R Greenland, Steven R Hays, Jeffrey A Golden, Aida Venado, Lorriana E Leard, Rupal J Shah, Mary Ellen Kleinhenz, Patricia P Katz, Jasleen Kukreja, Paul D Blanc, Patrick J Smith, Jonathan Paul Singer
Journal: Thorax (2022)

Objective Most studies observing an association between depressive symptoms following lung transplantation and mortality are limited to depressive symptom measurement at a single time point, unrelated to allograft function. We aimed to test the association of depressive symptoms over multiple assessments with allograft dysfunction and with mortality. Methods We assessed depressive symptoms before and serially up to 3 years after lung transplantation in lung transplant recipients. We quantified depressive symptoms with the Geriatric Depression Scale (GDS; range 0–15; minimally important difference (MID): 2). We quantified changes in GDS using linear mixed effects models and tested the association with mortality using Cox proportional hazards models with GDS as a time-dependent predictor. To determine if worsening in GDS preceded declines in lung function, we tested the association of GDS as a time-dependent predictor with the lagged outcome of FEV 1 at the following study visit. Results Among 266 participants, depressive symptoms improved early after transplantation. Worsening in post-transplant GDS by the MID was associated with mortality (HR 1.25, 95% CI 1.05 to 1.50), and in lagged outcome analyses with decreased per cent predicted FEV 1 (Δ, −1.62%, 95% CI −2.49 to –0.76). Visual analyses of temporal changes in GDS demonstrated that worsening depressive symptoms could precede chronic lung allograft dysfunction. Conclusions Depressive symptoms generally improve after lung transplantation. When they worsen, however, there is an association with declines in lung function and mortality. Depression is one of the few, potentially modifiable, risk factors for chronic lung allograft dysfunction and death.
Comparison of SARS-CoV-2 Reverse Transcriptase Polymerase Chain Reaction and BinaxNOW Rapid Antigen Tests at a Community Site During an Omicron Surge
Authors: John Schrom, Carina Marquez, Genay Pilarowski, Chung-Yu Wang, Anthea Mitchell, Robert Puccinelli, Doug Black, Susana Rojas, Salustiano Ribeiro, Valerie Tulier-Laiwa, Jacqueline Martinez, Joselin Payan, Susy Rojas, Diane Jones, Daniel Martinez, Robert Nakamura, Gabriel Chamie, Vivek Jain, Maya Petersen, Joe DeRisi, Diane Havlir
Journal: Annals of Internal Medicine (2022)

SARS-CoV-2 rapid antigen tests are an important public health tool.
Multilevel Factors for Adiposity Change in a Population-Based Prospective Study of Black Breast Cancer Survivors
Authors: Bo Qin, Kate Kim, Noreen Goldman, Andrew G. Rundle, Dhanya Chanumolu, Nur Zeinomar, Baichen Xu, Karen S. Pawlish, Christine B. Ambrosone, Kitaw Demissie, Chi-Chen Hong, Gina S. Lovasi, Elisa V. Bandera
Journal: Journal of Clinical Oncology (2022)

Unfavorable weight change after breast cancer diagnosis increases the risk of mortality, but individual and neighborhood risk factors affecting postdiagnosis weight and body fat changes are unclear among Black women, who have higher rates of obesity and mortality than any other racial/ethnic group.
Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma
Authors: Ying Wang, Jiang Cao, Weiying Gu, Ming Shi, Jianping Lan, Zhiling Yan, Lai Jin, Jieyun Xia, Sha Ma, Yang Liu, Hujun Li, Bin Pan, Wei Chen, Xiaoming Fei, Chunling Wang, Xiaobao Xie, Liang Yu, Gang Wang, Huizhong Li, Guangjun Jing, Hai Cheng, Feng Zhu, Haiying Sun, Wei Sang, Depeng Li, Zhenyu Li, Junnian Zheng, Kailin Xu
Journal: Journal of Clinical Oncology (2022)

A combination of anti-B-cell maturation antigen (BCMA) and anti-CD19 chimeric antigen receptor (CAR) T cells induced high response rates in patients with relapsed or refractory (R/R) multiple myeloma (MM), but long-term outcomes have not been assessed yet.In this single-arm, phase II trial, patients with R/R MM received a combination of anti-BCMA CAR T cells and anti-CD19 CAR T cells at a dose of 1 × 106 cells/kg, after receiving a conditioning chemotherapy consisting of cyclophosphamide and fludarabine. The overall response, long-term outcomes, and safety were assessed, as were their associations with clinical and disease characteristics.Of 69 enrolled patients, 62 received the combined infusion of anti-BCMA and anti-CD19 CAR T cells with a median follow-up of 21.3 months. The overall response rate was 92% (57/62), and complete response or better was observed in 37 patients (60%). Minimal residual disease-negativity was confirmed in 77% (43/56) of the patients with available minimal residual disease detection. The estimated median duration of response was 20.3 months (95% CI, 9.1 to 31.5). The median progression-free survival was 18.3 months (95% CI, 9.9 to 26.7), and the median overall survival was not reached. Patients with extramedullary disease had significantly inferior survival. Fifty-nine patients (95%) had cytokine release syndrome, with 10% grade 3 or higher. Neurotoxic events occurred in seven patients (11%), including 3% grade 3 or higher. Late adverse effects were rare, except for B-cell aplasia, hypogammaglobulinemia, and infections.The combination of anti-BCMA and anti-CD19 CAR T cells induced durable response in patients with R/R MM, with a median progression-free survival of 18.3 months and a manageable long-term safety profile.
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis—Coordinating Research Priorities to Move the Field Forward
Authors: Elizabeth J. Phillips, Charles S. Bouchard, Sherrie J. Divito
Journal: JAMA Dermatology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Follow-up Duration and Gender Differences in Study of Older Adults Living Alone
Authors: Mengyang He, Minjing Luo, Jinchang Huang
Journal: JAMA Internal Medicine (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
ASSESSMENT OF FLOW MEASUREMENTS USING A NONINVASIVE PHOTOPLETHYSMOGRAPHY BASED DEVICE COMPARED TO INVASIVE PULMONARY ARTERY CATHETER
Authors: Dean Nachman, Eldad Rahamim, Mahsati Ibrahimli, Asen Asenov, Nir Goldstein, Yotam Kolben, Segev Huly, Arik Ben Ishay, Meir Fons, Roei Merin, Arik Eisenkraft, Offer Amir, Rabea Asleh
Journal: Journal of the American College of Cardiology (2022)
HSR22-147: Experiences of Patients (pts) With Metastatic Breast Cancer (mBC) During the COVID-19 Pandemic in the United States: Results of the Rethink Access to Care &amp; Treatment (REACT) Survey
Authors: Neil Iyengar, Clay Williams, Michael Rogan, Laurie Campbell, Shirley Mertz, Jeremy Block, Maria Ebling, Connie Chen, Justin Doan, Samantha K. Kurosky, Timothy Pluard
Journal: Journal of the National Comprehensive Cancer Network (2022)

"HSR22-147: Experiences of Patients (pts) With Metastatic Breast Cancer (mBC) During the COVID-19 Pandemic in the United States: Results of the Rethink Access to Care & Treatment (REACT) Survey" published on 31 Mar 2022 by National Comprehensive Cancer Network.
Without more theory, psychology will be a headless rider
Authors: Witold M. Hensel, Marcin Miłkowski, Przemysław Nowakowski
Journal: Behavioral and Brain Sciences (2022)

Abstract We argue that Yarkoni's proposed solutions to the generalizability crisis are half-measures because he does not recognize that the crisis arises from investigators' underappreciation of the roles of theory in experimental research. Rather than embracing qualitative analysis, the research community should make an effort to develop better theories and work toward consistently incorporating theoretical results into experimental practice.
Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron
Authors: Gili Regev-Yochay, Tal Gonen, Mayan Gilboa, Michal Mandelboim, Victoria Indenbaum, Sharon Amit, Lilac Meltzer, Keren Asraf, Carmit Cohen, Ronen Fluss, Asaf Biber, Ital Nemet, Limor Kliker, Gili Joseph, Ram Doolman, Ella Mendelson, Laurence S Freedman, Dror Harats, Yitshak Kreiss, Yaniv Lustig
Journal: New England Journal of Medicine (2022)

recipients of either the BNT162b2 or mRNA-1273 vaccine), we observed 362 documented infections, including 23 participants with moderate disease and 8 with severe or critical disease.No material difference was noted in the incidence of SARS-CoV-2 infection, including moderate and severe or critical disease, among participants who had received heterologous or homologous boosting after primary mRNA vaccination (adjusted rate ratio, 1.10; 95% CI, 0.90 to 1.35).Outcomes for the individual mRNA vaccines were similar to those in the combined mRNA category.(Additional data regarding individual vaccines are provided in Table S2.)Recent clinical trials examining the safety and immunogenicity of SARS-CoV-2 boosters in healthy adults have shown greater increases in antibody titers after heterologous boosting than after homologous boosting. 2,5 In particular, neutralizing immunoglobulin G antibodies were lowest after homologous Ad26.COV2.S boosting and remained below the predicted efficacy threshold for preventing symptomatic Covid-19. 2ur findings support the results of these clinical trials since we observed the largest number of documented breakthrough infections in participants who had received a homologous Ad26.COV2.S booster.Our analysis provides further evidence that the infection rate is lower in persons who are boosted with a heterologous mRNA vaccine.Overall, documented infections, including moderate and severe or critical disease, were uncommon among veterans who had received either homologous or heterologous boosters.Heterologous mRNA boosting may better protect against incident infection in persons who were initially vaccinated with an adenoviralvector vaccine.
Dietary manipulation of the gut microbiome in inflammatory bowel disease patients: Pilot study
Authors: Barbara Olendzki, Vanni Bucci, Caitlin Cawley, Rene Maserati, Margaret McManus, Effie Olednzki, Camilla Madziar, David Chiang, Doyle V. Ward, Randall Pellish, Christine Foley, Shakti Bhattarai, Beth A. McCormick, Ana Maldonado-Contreras
Journal: Gut Microbes (2022)

Diet is a modifiable, noninvasive, inexpensive behavior that is crucial in shaping the intestinal microbiome. A microbiome "imbalance" or dysbiosis in inflammatory bowel disease (IBD) is linked to inflammation. Here, we aim to define the impact of specific foods on bacterial species commonly depleted in patients with IBD to better inform dietary treatment. We performed a single-arm, pre-post intervention trial. After a baseline period, a dietary intervention with the IBD-Anti-Inflammatory Diet (IBD-AID) was initiated. We collected stool and blood samples and assessed dietary intake throughout the study. We applied advanced computational approaches to define and model complex interactions between the foods reported and the microbiome. A dense dataset comprising 553 dietary records and 340 stool samples was obtained from 22 participants. Consumption of prebiotics, probiotics, and beneficial foods correlated with increased abundance of Clostridia and Bacteroides, commonly depleted in IBD cohorts. We further show that specific foods categorized as prebiotics or adverse foods are correlated to levels of cytokines in serum (i.e., GM-CSF, IL-6, IL-8, TNF-alpha) that play a central role in IBD pathogenesis. By using robust predictive analytics, this study represents the first steps to detangle diet-microbiome and diet-immune interactions to inform personalized nutrition for patients suffering from dysbiosis-related IBD.
An integrative approach of digital image analysis and transcriptome profiling to explore potential predictive biomarkers for TGFβ blockade therapy
Authors: Robert Pomponio, Qi Tang, Anthony Mei, Anne Caron, Bema Coulibaly, Joachim Theilhaber, Maximilian Rogers-Grazado, Michele Sanicola-Nadel, Souad Naimi, Reza Olfati-Saber, Cecile Combeau, Jack Pollard, Tun Tun Lin, Rui Wang
Journal: Acta Pharmaceutica Sinica B (2022)

Increasing evidence suggests that the presence and spatial localization and distribution pattern of tumor infiltrating lymphocytes (TILs) is associate with response to immunotherapies. Recent studies have identified TGFβ activity and signaling as a determinant of T cell exclusion in the tumor microenvironment and poor response to PD-1/PD-L1 blockade. Here we coupled the artificial intelligence (AI)-powered digital image analysis and gene expression profiling as an integrative approach to quantify distribution of TILs and characterize the associated TGFβ pathway activity. Analysis of T cell spatial distribution in the solid tumor biopsies revealed substantial differences in the distribution patterns. The digital image analysis approach achieves 74% concordance with the pathologist assessment for tumor-immune phenotypes. The transcriptomic profiling suggests that the TIL score was negatively correlated with TGFβ pathway activation, together with elevated TGFβ signaling activity observed in excluded and desert tumor phenotypes. The present results demonstrate that the automated digital pathology algorithm for quantitative analysis of CD8 immunohistochemistry image can successfully assign the tumor into one of three infiltration phenotypes: immune desert, immune excluded or immune inflamed. The association between "cold" tumor-immune phenotypes and TGFβ signature further demonstrates their potential as predictive biomarkers to identify appropriate patients that may benefit from TGFβ blockade.
Gold nanorods modified by endogenous protein with light-irradiation enhance bone repair via multiple osteogenic signal pathways
Authors: Huajian Shan, Xuanfang Zhou, Bo Tian, Chenyu Zhou, Xiang Gao, Chaowen Bai, Bingchen Shan, Yingzi Zhang, Shengxuan Sun, Dongdong Sun, Qin Fan, Xiaozhong Zhou, Chao Wang, Jinyu Bai
Journal: Biomaterials (2022)
THE NOVEL SIMPLE EQUATION FOR ESTIMATING APPENDICULAR SKELETAL MUSCLE MASS PREDICTED ADVERSE OUTCOMES IN PATIENTS WITH CORONARY ARTERY DISEASE
Authors: Ryota Nishio, Tomotaka Dohi, Tatsuya Fukase, Mitsuhiro Takeuchi, Norihito Takahashi, Hirohisa Endo, Shinichiro Doi, Iwao Okai, Hiroshi Iwata, Shinya Okazaki, Katsumi Miyauchi, Hiroyuki Daida, Tohru Minamino
Journal: Journal of the American College of Cardiology (2022)
Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma
Authors: Richard D. Carvajal, Paul Nathan, Joseph J. Sacco, Marlana Orloff, Leonel F. Hernandez-Aya, Jessica Yang, Jason J. Luke, Marcus O. Butler, Sarah Stanhope, Laura Collins, Cheryl McAlpine, Chris Holland, Shaad E. Abdullah, Takami Sato
Journal: Journal of Clinical Oncology (2022)

PURPOSE This phase I study aimed to define the recommended phase II dose (RP2D) of tebentafusp, a first-in-class T-cell receptor/anti-CD3 bispecific protein, using a three-week step-up dosing regimen, and to assess its safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity in patients with metastatic uveal melanoma (mUM). METHODS In this open-label, international, phase I/II study, HLA-A*02 or HLA-A*02:01+ patients with mUM received tebentafusp 20 μg once in week 1 and 30 μg once in week 2. Dose escalation (starting at 54 μg) began at week 3 in a standard 3 + 3 design to define RP2D. Expansion-phase patients were treated at the RP2D (20-30-68 μg). Blood and tumor samples were collected for pharmacokinetics/pharmacodynamics assessment, and treatment efficacy was evaluated for all patients with baseline efficacy data as of December 2017. RESULTS Between March 2016 and December 2017, 42 eligible patients who failed a median of two previous treatments were enrolled: 19 in the dose escalation cohort and 23 in an initial dose expansion cohort. Of the dose levels investigated, 68 μg was identified as the RP2D. Most frequent treatment-emergent adverse events regardless of attribution were pyrexia (91%), rash (83%), pruritus (83%), nausea (74%), fatigue (71%), and chills (69%). Toxicity attenuated following the first three doses. The overall response rate was 11.9% (95% CI, 4.0 to 25.6). With a median follow-up of 32.4 months, median overall survival was 25.5 months (range, 0.89-31.1 months) and 1-year overall survival rate was 67%. Treatment was associated with increased tumor T-cell infiltration and transient increases in serum inflammatory mediators. CONCLUSION Using a step-up dosing regimen of tebentafusp allowed a 36% increase in the RP2D compared with weekly fixed dosing, with a manageable side-effect profile and a signal of efficacy in mUM.
Presynaptic autophagy is coupled to the synaptic vesicle cycle via ATG-9
Authors: Sisi Yang, Daehun Park, Laura Manning, Sarah E. Hill, Mian Cao, Zhao Xuan, Ian Gonzalez, Yongming Dong, Benjamin Clark, Lin Shao, Ifechukwu Okeke, Agustin Almoril-Porras, Jihong Bai, Pietro De Camilli, Daniel A. Colón-Ramos
Journal: Neuron (2022)

Autophagy is a cellular degradation pathway essential for neuronal health and function. Autophagosome biogenesis occurs at synapses, is locally regulated, and increases in response to neuronal activity. The mechanisms that couple autophagosome biogenesis to synaptic activity remain unknown. In this study, we determine that trafficking of ATG-9, the only transmembrane protein in the core autophagy pathway, links the synaptic vesicle cycle with autophagy. ATG-9-positive vesicles in C. elegans are generated from the trans-Golgi network via AP-3-dependent budding and delivered to presynaptic sites. At presynaptic sites, ATG-9 undergoes exo-endocytosis in an activity-dependent manner. Mutations that disrupt endocytosis, including a lesion in synaptojanin 1 associated with Parkinson's disease, result in abnormal ATG-9 accumulation at clathrin-rich synaptic foci and defects in activity-induced presynaptic autophagy. Our findings uncover regulated key steps of ATG-9 trafficking at presynaptic sites and provide evidence that ATG-9 exo-endocytosis couples autophagosome biogenesis at presynaptic sites with the activity-dependent synaptic vesicle cycle.
Characterization of the genetic architecture of infant and early childhood body mass index
Authors: Øyvind Helgeland, Marc Vaudel, Pol Sole-Navais, Christopher Flatley, Julius Juodakis, Jonas Bacelis, Ingvild L. Koløen, Gun Peggy Knudsen, Bente B. Johansson, Per Magnus, Ted Reichborn Kjennerud, Petur B. Juliusson, Camilla Stoltenberg, Oddgeir L. Holmen, Ole A. Andreassen, Bo Jacobsson, Pål R. Njølstad, Stefan Johansson
Journal: Nature Metabolism (2022)
Evaluation of Comparative Surveillance Strategies of Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen Levels in Patients With Resected Colorectal Cancer
Authors: Marwan Fakih, Jaideep Sandhu, Chongkai Wang, Jae Kim, Yi-Jen Chen, Lily Lai, Kurt Melstrom, Andreas Kaiser
Journal: JAMA Network Open (2022)

A circulating tumor DNA (ctDNA) assay (Signatera; Natera) has been marketed for use in the surveillance of resected colorectal cancer despite limited data supporting such practice.To compare a ctDNA assay with standard radiographic imaging and measurement of carcinoembryonic antigen (CEA) levels, per National Comprehensive Cancer Network guidelines, in the surveillance of resected colorectal cancer.This retrospective, single-center cohort study evaluated surveillance strategies of ctDNA, imaging, and measurement of CEA levels in patients with resected colorectal cancer from September 1, 2019, to November 30, 2021.The sensitivity and specificity of ctDNA, imaging, measurement of CEA levels, and combination of imaging plus measurement of CEA levels in detecting a confirmed recurrence of colorectal disease. A confirmed recurrence was defined as a positive ctDNA finding or a finding on imaging confirmed by biopsy, CEA level elevation, or subsequent tumor radiographic dynamics.A total of 48 patients with curatively resected colorectal cancer satisfied the inclusion criteria for this study (28 men [58.3%]; median age, 60 [IQR, 34-85] years) and underwent surveillance by ctDNA, imaging, and measurement of CEA levels. Fifteen patients had disease recurrence during surveillance. Positive ctDNA findings confirmed disease recurrence in 8 patients; imaging, in 9 patients; CEA levels, in 3 patients; and combined imaging plus CEA levels, in 11 patients. Numerically, ctDNA did not perform better than imaging in detecting recurrence, with sensitivities of 53.3% (95% CI, 27.4%-77.7%) and 60.0% (95% CI, 32.9%-82.5%), respectively (P > .99). The combination of imaging plus measurement of CEA levels (sensitivity, 73.3% [95% CI, 44.8%-91.1%]) had a numerical advantage compared with ctDNA in identifying recurrence (P = .55). In addition, no significant difference was noted among ctDNA (median, 14.3 months), imaging (median, 15.0 months), or imaging plus measurement of CEA levels (median, 15.0 months) in the time to identify disease recurrence.The findings of this cohort study suggest that ctDNA assay may not provide advantages as a surveillance strategy compared with standard imaging combined with CEA levels when performed per National Comprehensive Cancer Network guidelines.